Qualigen

Qualigen is a biotechnology company that focuses on the developing and commercializing novel therapeutic products for the treatment of cancer and other infectious diseases, as well as the expansion of its flagship product, FastPack® diagnostic platform.

Its therapeutics pipeline includes cancer drug candidate compounds such as AS1411, ALAN, the RAS-F family of drug candidate compounds, as well as STARS, a DNA/RNA-based treatment device.

The company is committed to providing new therapeutic technologies to physicians and patients by combining its demonstrated ability to develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers like the University of Louisville.

Qualigen’s AS1411 cancer drug candidate uses synthetic DNA, known as an aptamer, to target and destroy tumor cells, without the serious side effects associated with other cancer therapies.